http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102397548-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-706 |
| filingDate | 2010-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102397548-B |
| titleOfInvention | Medicinal composition containing arctigenin and medical application thereof |
| abstract | The invention relates to a medicinal composition containing arctigenin and application thereof to preparation of a medicament for treating the myelodysplastic syndrome (MDS). The medicinal composition comprises arctigenin serving as an active ingredient and a DNA (Deoxyribonucleic Acid) methylated transferase inhibitor, wherein the DNA methylated transferase inhibitor comprises decitabine and 5-azacitidine. The medicinal composition disclosed by the invention has a synergistic action for inhibiting the growth of a MDS-RAEB (Myelodysplastic Syndrome-Refractory Anemia with Excess Blast) cell strain SKM-1, and can be used for better treating the MDS. |
| priorityDate | 2010-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.